Virax Biolabs Group (VRAX) Competitors $0.66 +0.01 (+1.54%) Closing price 03:53 PM EasternExtended Trading$0.67 +0.01 (+1.41%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. AEON, IMCC, BFRI, SNPX, CARM, INAB, KALA, PHXM, ERNA, and RNAZShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include AEON Biopharma (AEON), IM Cannabis (IMCC), Biofrontera (BFRI), Synaptogenix (SNPX), Carisma Therapeutics (CARM), IN8bio (INAB), KALA BIO (KALA), PHAXIAM Therapeutics (PHXM), Ernexa Therapeutics (ERNA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors AEON Biopharma IM Cannabis Biofrontera Synaptogenix Carisma Therapeutics IN8bio KALA BIO PHAXIAM Therapeutics Ernexa Therapeutics TransCode Therapeutics AEON Biopharma (NASDAQ:AEON) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Which has preferable earnings & valuation, AEON or VRAX? Virax Biolabs Group has higher revenue and earnings than AEON Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAEON BiopharmaN/AN/A-$36.63M-$6.08-0.19Virax Biolabs Group$10K286.74-$6.06MN/AN/A Do analysts prefer AEON or VRAX? Virax Biolabs Group has a consensus price target of $3.00, indicating a potential upside of 354.06%. Given Virax Biolabs Group's higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than AEON Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Virax Biolabs Group 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, AEON or VRAX? AEON Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Does the media favor AEON or VRAX? In the previous week, Virax Biolabs Group had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Virax Biolabs Group and 1 mentions for AEON Biopharma. Virax Biolabs Group's average media sentiment score of 0.95 beat AEON Biopharma's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media. Company Overall Sentiment AEON Biopharma Neutral Virax Biolabs Group Positive Do institutionals & insiders have more ownership in AEON or VRAX? 22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is AEON or VRAX more profitable? Company Net Margins Return on Equity Return on Assets AEON BiopharmaN/A N/A -994.63% Virax Biolabs Group N/A N/A N/A SummaryVirax Biolabs Group beats AEON Biopharma on 8 of the 10 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.83M$3.36B$6.06B$10.53BDividend YieldN/A2.31%5.73%4.79%P/E RatioN/A7.9164.4523.40Price / Sales286.74473.61593.63135.47Price / CashN/A46.9537.5761.53Price / Book0.5210.4312.676.74Net Income-$6.06M-$52.58M$3.32B$276.59M7 Day Performance3.07%0.98%0.50%0.86%1 Month Performance10.86%14.76%9.42%8.17%1 Year Performance-63.50%21.29%79.11%43.66% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.0064 of 5 stars$0.66+1.5%$3.00+354.1%-63.6%$2.83M$10K0.005Analyst ForecastAEONAEON Biopharma0.9291 of 5 stars$0.94+10.0%N/A-98.5%$10.89MN/A5.205Gap DownIMCCIM Cannabis0.6528 of 5 stars$2.02-2.4%N/A-13.7%$10.86M$39.44M-3.74340BFRIBiofrontera2.3763 of 5 stars$1.03-3.3%$2.75+168.3%+17.8%$10.75M$37.32M0.0070SNPXSynaptogenixN/A$7.71+20.3%N/A+132.8%$10.72MN/A-0.764Gap UpCARMCarisma Therapeutics2.4757 of 5 stars$0.26+2.5%$1.93+633.6%-95.1%$10.70M$19.63M-0.1720Gap UpINABIN8bio2.6055 of 5 stars$2.46+4.7%$180.00+7,217.1%-67.9%$10.67MN/A-0.2720News CoverageAnalyst ForecastKALAKALA BIO4.1163 of 5 stars$1.64+7.9%$20.38+1,142.4%-71.7%$10.67M$3.89M-0.2430PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ERNAErnexa Therapeutics1.046 of 5 stars$1.31-3.7%N/A-91.7%$10.43M$580K0.0010Gap DownRNAZTransCode Therapeutics2.1797 of 5 stars$11.94+1.2%$280.00+2,245.3%-99.9%$9.84MN/A0.009News Coverage Related Companies and Tools Related Companies AEON Biopharma Competitors IM Cannabis Competitors Biofrontera Competitors Synaptogenix Competitors Carisma Therapeutics Competitors IN8bio Competitors KALA BIO Competitors PHAXIAM Therapeutics Competitors Ernexa Therapeutics Competitors TransCode Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
